Business
Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial
The first five patients successfully completed protocols with no immediate procedural-related complications or significant adverse events; Pain relief for
About this update from Autonomix Medical, Inc.
[{"type":"text","content":"The first five patients successfully completed protocols with no immediate procedural-related complications or significant adverse events; Pain relief for responder group was experienced as quick as 1 day post-procedure 60% of subjects responded with a mean 6.33 reduction of pain on the VAS pain scale (from baseline of 8.0 to 1.67) at 7 days post-procedure 100% of this responder group had clinically meaningful pain relief at 7 days post-procedure Responder patients reported a mean 78% improvement in quality of health and mean 45% improvement in quality of life at 7 days post-procedure Trial remains on track to complete enrollment by year-end 2024 Management to host live webcast to discuss results today, June 18th at 8:30 a.m. ET THE WOODLANDS, TX, June 18, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced preliminary positive results from the first five “lead-in” patients in the Company’s ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. The goal of this trial is to assess pain reduction via radiofrequency (RF) ablation. The Company’s catheter-based microchip sensing array used to detect and differentiate neural signaling was not used in this trial and will be evaluated in future studies. As previously announced, management will host a webcast presentation to discuss the preliminary results today, Tuesday, June 18, 2024, at 8:30 a.m. ET (details below). The first five patients were enrolled and treated according to protocol in the beginning of the trial to familiarize the Principal Investigator (PI) with the procedure and will not be included in the analysis of the trial objectives. These first five “lead-in” patients successfully completed the procedure per protocol with no immediate procedural-related complications or significant adverse events. “We are very pleased with these initial positive results, which confirm our ability to treat this historically difficult-to-treat cancer pain with catheter-based transvascular RF ablation. While preli...